Another study revealed differential expression of exosomal miR-101 and miR-373 between patients with breast cancer and benign breast tumors; exosomal miR-101 serum levels were dysregulated in HER2-positive breast cancer compared with their levels in healthy women [184]. This evidence concerns the gene ERBB2 and breast carcinoma.